Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
GSK axes key cough drug candidate after phase 3 data disappoint
GSK ended development after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as a key catalyst.
Nick Paul Taylor
Jul 17, 2026 5:46am
Bausch + Lomb gives up on glaucoma eye drop hopeful after fail
Jul 10, 2026 7:31am
Roche ends 2 Huntington’s programs, including Ionis ASO
Jul 9, 2026 2:40pm
GSK cuts losses on $700M upfront Alzheimer’s collab with Alector
Jul 9, 2026 7:30am
Merck halts ph. 2 Alzheimer’s trial after underwhelming efficacy
Jul 1, 2026 2:35pm
Pressure of biopharma layoffs continues to ease in Q2'26
Jul 1, 2026 10:30am
